Insuman Comb 25

Insulin Human, the active ingredient in Insuman Comb 25, is an insulin presented as a subcutaneous injectable for diabetes management. It is used to control blood glucose levels in patients with insulin‑dependent diabetes.\nGNH India supplies Insuman Comb 25 as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Insuman Comb 25 is an insulin analogue that acts on the glucose regulation pathway to manage hyperglycaemia in diabetes.\n\n- Type 1 diabetes mellitus: provides basal and prandial insulin coverage to replace the absent endogenous insulin, helping maintain target glycaemic ranges.\n- Type 2 diabetes mellitus: supplements endogenous insulin production and improves post‑prandial glucose control when oral agents are insufficient.

Insuman Comb 25 may be associated with a range of adverse reactions.\n\nCommon Side Effects:\n- Hypoglycaemia: low blood glucose episodes, especially if meals are missed or dosing is excessive.\n- Injection‑site reactions: redness, swelling, or bruising at the injection site.\n- Weight gain: modest increase due to improved glucose utilisation.\n- Lipodystrophy: localized fat accumulation or loss with repeated injections.\n- Edema: mild peripheral swelling, particularly in the lower limbs.\n\nSerious or Rare Side Effects:\n- Severe hypoglycaemia leading to seizures or loss of consciousness.\n- Anaphylactic reaction: urticaria, bronchospasm, or angio‑edema requiring emergency care.\n- Hypokalemia: low serum potassium levels, especially with high insulin doses.\n- Insulin allergy: systemic hypersensitivity manifesting as fever, rash, or organ involvement.

When using Insuman Comb 25, clinicians and patients should observe several safety measures.\n\n- Dose adjustment: tailor the insulin dose to individual glucose monitoring results and lifestyle factors.\n- Blood‑glucose monitoring: perform frequent self‑monitoring to detect hypoglycaemia early.\n- Renal impairment: reduce dose cautiously as reduced clearance can increase hypoglycaemia risk.\n- Pregnancy and lactation: use only if clearly needed; benefits must outweigh potential risks.\n- Store at 2-8°C: keep refrigerated, protect from light, do not freeze or shake the vial.

Insuman Comb 25 can interact with several drug classes, influencing glucose control or insulin action.\n\nMajor Interactions (Avoid):\n- Concurrent sulfonylureas or meglitinides: may cause severe hypoglycaemia.\n- Beta‑blockers: can mask typical hypoglycaemia symptoms such as tachycardia.\n\nModerate Interactions (Monitor Closely):\n- ACE inhibitors or ARBs: may potentiate insulin’s glucose‑lowering effect.\n- Thiazide diuretics: can raise blood glucose, requiring dose reassessment.\n- Oral contraceptives: may alter insulin requirements during hormonal changes.